Imatinib helpful after interferon fails in CML treatment
A long-term study indicated that imatinib is the treatment of choice for people with chronic myeloid leukemia who do not respond to interferon.
Diagnosis & Disease Information
New drugs change treatment landscape for advanced prostate cancer
Several newly approved drugs plus more in the pipeline present the real possibility of prolonging survival in men with advanced prostate cancer.
Antiangiogenics could be effective against new ovarian cancer subtype
A newly identified subtype of ovarian cancer that builds its own blood vessels may be vulnerable to agents that block blood vessel formation.
NSAIDs may thwart cancer metastasis
Common over-the-counter agents that are known inhibitors of prostaglandin synthesis were shown to inhibit tumor metastasis into lymph nodes.
ACS updates recommendations for cancer prevention
The American Cancer Society has updated its 2006 guidelines on nutrition and physical activity for cancer prevention.
Diabetes drug reduces cancer mortality
Cancer patients with diabetes who took metformin were found to have a significantly lower overall mortality than cancer patients without diabetes.
Vaccine used in early breast cancer shows good immunity response
Many women with early breast cancer experienced a sustained immune response after immunization with a vaccine that fights HER2, and this may reduce their risk for more invasive cancer.
Gleevec wins wider approval for use in GI cancer
Gleevec (imatinib mesylate) has been granted regular approval by the FDA for use in adults following surgical removal of CD117-positive gastrointestinal stromal tumors (GIST).
Melanoma treatment creates risk of secondary skin cancer
Investigators have discovered why the pill Zelboraf (vemurafenib), effective against melanoma, may also cause the development of a secondary skin cancer: squamous cell carcinoma.
Experimental agent slows progression of colorectal cancer
The investigational drug regorafenib conferred a statistically significant survival benefit in patients with metastatic colorectal cancer in whom no standard therapy was effective.
- Loading...
Loading...
Loading... 
Loading...